Wall Street analysts expect that Immatics (NASDAQ:IMTX) will report earnings of ($0.33) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Immatics’ earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.35). The company is expected to announce its next quarterly earnings report on Wednesday, March 3rd.
On average, analysts expect that Immatics will report full year earnings of ($5.09) per share for the current year, with EPS estimates ranging from ($5.66) to ($4.01). For the next fiscal year, analysts expect that the business will report earnings of ($1.29) per share, with EPS estimates ranging from ($1.51) to ($1.14). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Immatics.
Immatics (NASDAQ:IMTX) last released its earnings results on Tuesday, December 1st. The company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($2.56). The business had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.03 million.
Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Immatics in the 4th quarter valued at $83,000. Morgan Stanley acquired a new stake in Immatics during the 3rd quarter worth $99,000. GWM Advisors LLC purchased a new stake in Immatics in the third quarter valued at $106,000. LPL Financial LLC acquired a new position in Immatics in the third quarter valued at $115,000. Finally, Granite Point Capital Management L.P. acquired a new position in Immatics in the third quarter valued at $150,000.
Immatics stock traded up $0.05 during mid-day trading on Tuesday, reaching $11.07. 3,265 shares of the company’s stock were exchanged, compared to its average volume of 115,822. Immatics has a twelve month low of $8.66 and a twelve month high of $17.48. The company has a fifty day moving average of $11.07 and a 200-day moving average of $10.44.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Article: dividend yield calculator
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.